Published: 2. February, 2026
Welcome to the first quarter of 2026 2025 has been a year of significant…
Welcome to the first quarter of 2026
2025 has been a year of significant progress for Cessatech. Our work is dedicated to improving the treatment of acute pain in children, benefiting patients, families and healthcare professionals. Throughout the year, we have continued to advance our lead paediatric programme, and we enter 2026 positioned for what we expect to be a transformative year for the company.
All hands on deck to support the coming US launch
In the US, the collaboration with Ventis Pharma (commercial partner) and STAQ Pharma (manufacturing partner) is progressing well, and all efforts are focused on finalizing the marketing and training materials needed prior to the US launch.
The requisite development batches have been successfully produced, and stability studies are currently ongoing. This represents the concluding quality assurance step prior to market release. Note that for the US market, we are validating compliance against specific FDA requirements, which entail distinct acceptance criteria compared to the EMA framework. Upon confirmation of the final stability data from our manufacturing partner, the product can be released to hospitals.
